BioBusiness

Brazil's regulatory health authority, Anvisa, plans to establish quality requirements for locally produced pharmaceutical excipients, Anvisa told BioPharm International.

After a series of government reforms, the Japanese pharma market is making a comeback.

A team from Northwestern University has demonstrated the feasibility of topical delivery of small interfering RNA (siRNA).

Now that the Supreme Court has upheld the Affordable Care Act, what's next for biopharma?

Steven S. Kuwahara, PhD, principal consultant at GXP BioTechnology LLC, gives an update on "Engineering the Cell-System Interface."

Collaborative R&D models coincide with new ways to fund translational research.

Selection of the right cell line, culture medium, and bioreactor conditions is key to setting up the upstream portion of the biopharmaceutical manufacturing process.

BIO is calling for a more patient-centric approach to user-fee reauthorization.

In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.

The contract provider needs to know as much as the NDA holder.

Mike Clayman, CEO of Flexion Therapeutics, talks about his company's strategy to focus on a single therapeutic area.

A review of key industry shifts and promises for the future.

Formulators and developers are at the heart of the industry's basic premise-they are saving lives.

Industry experts discuss significant achievements. Plus: What's in store for the future.

Service providers must focus on delivering a superior customer experience.

This month, we rewind to an article titled "The Biotechnology Industry: A First Quarter Snapshot."

Future sponsor-contract provider relationships will require more integration.

BioPharm talks with Tarja Mottram, CEO of Action for Results, on design-for-value concepts, management, and cross-functionality.

Better news about the global economy buoys life-sciences funding.

FDA has created a dedicated cadre of foreign drug investigators and established permanent offices worldwide.

Rather than seeking a single indication for one large group, the orphan-drug approach segments the market for a drug more minutely.

Soaring opioid use creates challenges for new drug development and supply-chain control.

A closer look at elastomer changeout times provides one example of using industry knowledge to improve operations and cost.

The authors discuss the technology and guidance required to achieve good KM in a biopharmaceutical company.

Recovery audits and other best practices in procurement can improve the bottom line.